Search research articles
Contact Us
Filters
Showing results (111-120 of 174) with videos related to
Page
of 18
Sort By:
American Journal of Hematology
|
October 24, 2025
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy
Heinz Ludwig, Meletios Athanasios Dimopoulos, Evangelos Terpos, et al.
Haematologica
|
October 4, 2015
European Myeloma Network guidelines for the management of multiple myeloma-related complications
Evangelos Terpos, Martina Kleber, Monika Engelhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2020
Standardization of <sup>18</sup>F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
Elena Zamagni, Cristina Nanni, Luca Dozza, et al.
Nature Immunology
|
April 10, 2024
An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma
Madelon M E de Jong, Cathelijne Fokkema, Natalie Papazian, et al.
Eclinicalmedicine
|
July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
Stefania Oliva, Elisa Genuardi, Laura Paris, et al.
Haematologica
|
July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Pellegrino Musto, Monika Engelhardt, Jo Caers, et al.
The Lancet. Oncology
|
November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
The Lancet. Oncology
|
November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Hemasphere
|
August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
Grigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 174) with videos related to
Sort By:
Page
of 18
American Journal of Hematology
|
October 24, 2025
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy
Heinz Ludwig, Meletios Athanasios Dimopoulos, Evangelos Terpos, et al.
Haematologica
|
October 4, 2015
European Myeloma Network guidelines for the management of multiple myeloma-related complications
Evangelos Terpos, Martina Kleber, Monika Engelhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2020
Standardization of <sup>18</sup>F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
Elena Zamagni, Cristina Nanni, Luca Dozza, et al.
Nature Immunology
|
April 10, 2024
An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma
Madelon M E de Jong, Cathelijne Fokkema, Natalie Papazian, et al.
Eclinicalmedicine
|
July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
Stefania Oliva, Elisa Genuardi, Laura Paris, et al.
Haematologica
|
July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Pellegrino Musto, Monika Engelhardt, Jo Caers, et al.
The Lancet. Oncology
|
November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
The Lancet. Oncology
|
November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Hemasphere
|
August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
Grigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.
Page
of 18